RxDoctor Payments Data

Stanley Hall, MD

Urology · Mt Pleasant, SCNPI 1003815259

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,794 of the $7,669 with a category attached, or 75.5%. It is spread thinly across 43 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,434, 2.1 times the $1,174 reported in 2019.

$7,669in general payments, 2019–2025

Across 236 payments — averaging $32.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$865
  • Angiodynamics, Inc.$702
  • Boston Scientific$677
  • Axonics, Inc.$597
  • Johnson & Johnson$408
  • Urogen Pharma, Inc.$334
  • plus $4K from 37 others

What the payments were for

  • Travel & lodging$1,71722%
  • Food & beverage$5,79476%
  • Education$1582%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,669 in reported general payments places this provider in the 75th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$475,286
Medicare patients
952
Services billed
10,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix57$148,773
MyrbetriqMirabegron185$143,469
GemtesaVibegron30$18,779
Tamsulosin Hcl718$11,403
Mirabegron ErMirabegron14$8,176
Silodosin66$5,520
Potassium Citrate ErPotassium Citrate49$4,048
Solifenacin Succinate95$3,751
Dutasteride59$1,821
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav29$1,447
Trimethoprim34$1,348
Finasteride70$878
Estradiol11$441
Oxybutynin Chloride ErOxybutynin Chloride13$378
Alfuzosin Hcl ErAlfuzosin Hcl12$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$216$167,55287 claims
Astellas Pharma US IncMyrbetriq$326$143,469185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 196 urology providers in South Carolina.

Other urology in Mt Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →